Petco surges 16% as pet retailer boosts full-year outlook after strong profit beat

Petco Health and Wellness Company (WOOF) shares surged over 16% in premarket trading after exceeding Q2 earnings expectations and raising its full-year adjusted EBITDA guidance. The company reported adjusted EPS of $0.05 and revenue of $1.5 billion, while robust profitability improvements saw adjusted EBITDA reach $113.9 million, significantly beating guidance despite a 2.3% year-over-year sales decline. This strong profit execution, which led to a raised FY25 adjusted EBITDA outlook of $385-$395 million, underscores Petco's successful economic model transformation and potential for further re-rating, despite ongoing comparable sales challenges.

Analysis

Petco Health and Wellness (WOOF) demonstrated significant progress in its operational turnaround during the second quarter, catalyzing a more than 16% premarket share price increase. Despite a challenging top-line environment, evidenced by a 2.3% year-over-year revenue decline to $1.5 billion and a 1.4% drop in comparable sales, the company's profitability metrics substantially outperformed expectations. The key driver was a 120 basis point expansion in gross profit margin to 39.3%, which propelled adjusted EBITDA to $113.9 million—a more than 20% beat against its own guidance. This strong bottom-line execution enabled the company to post adjusted EPS of $0.05, well ahead of the $0.01 consensus. Consequently, management raised its full-year FY25 adjusted EBITDA forecast to a range of $385-$395 million, with the midpoint now exceeding analyst consensus. While analysts note the near-term revenue outlook remains challenged, the results signal that Petco's profit improvement strategy is highly effective, setting the stage for a potential re-rating if the company can pivot back to positive comparable sales growth in FY26.

Key Decisions for Investors

• Investors should recognize that Petco's strong execution on profitability, evidenced by a significant Q2 EBITDA beat and raised full-year guidance, confirms the company's operational turnaround is ahead of plan.
• The primary risk remains the negative top-line performance; therefore, it is critical to monitor for a stabilization and eventual return to positive comparable sales, which an analyst has identified as the key catalyst for further upside.
• Given the successful profit improvement, consider the stock as a turnaround play where the current valuation is supported by margin expansion, but future re-rating depends on the company successfully entering its 'Phase 3' of returning to growth.